NEW YORK (TheStreet) -- BMO Capital Markets lowered its price target for Monsanto (MON) to $127 from $132 on Thursday, maintaining its "outperform" rating for the agrochemical and agricultural biotechnology company.
The analyst firm lowered its fiscal 2015 EPS estimates for the company to $5.78 a share from its previous estimate of $5.81 a share. BMO also lowered its fiscal 2016 and 2017 EPS estimates for the company to $6.30 and $7.29 a share from $6.68 and $7.99 a share, respectively.
BMO analysts Joel Jackson and Milan Shah noted that Monsanto beat analysts' estimates for the fiscal third quarter thanks to its Scotts brand licensing and help its fiscal 2015 EPS guidance, but said that "commentary on FX/ag/margin headwinds is bearish."
The analysts continued, "The bearish short-term outlook (FX and crop price/acreage reduction headwinds) will likely lead to a cut to consensus F2016/17 estimates."
Separately, TheStreet Ratings team rates MONSANTO CO as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:
"We rate MONSANTO CO (MON) a BUY. This is driven by a few notable strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its expanding profit margins, good cash flow from operations, notable return on equity, largely solid financial position with reasonable debt levels by most measures and attractive valuation levels. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself."